# Temozolomide (TMZ) Dosing Protocols for Glioblastoma

## Standard Stupp Protocol

### Concomitant Radiotherapy Phase (6-7 weeks)
- **Dose**: 75 mg/m² PO daily
- **Duration**: 42-49 consecutive days
- **Concurrent treatment**: Focal radiotherapy (60 Gy total, 2 Gy/fraction)
- **Monitoring**: Weekly CBC

### Adjuvant/Maintenance Phase (6 cycles standard)
- **Cycle 1**: 150 mg/m² PO daily × 5 days, every 28 days
- **Cycles 2-6**: 200 mg/m² PO daily × 5 days (if tolerated)
- **28-day treatment break** after concomitant phase

### Extended Treatment Protocol (2024 Evidence)
- **Duration**: Up to 12 cycles showing improved outcomes
- **Evidence**: 12 cycles vs 6 cycles improved OS (22.8 vs 17.5 months)
- **HR**: 0.47 (95% CI: 0.30-0.73, P=0.001)

## Administration Guidelines

### Timing and Food Interactions
- **Administration**: On empty stomach
- **Fluid**: With full glass of water
- **Food restriction**: Avoid food 2 hours before and after
- **Rationale**: Food increases gastric irritation and unpredictable absorption

### Capsule Information
- **Available strengths**: 5, 20, 100, 140, 180, 250 mg
- **Dosing rule**: Round to nearest 5 mg
- **Route**: Oral (PO) or IV if necessary

### Antiemetic Prophylaxis
- **Recommended**: Especially during maintenance phase
- **Timing**: Pre-medication 30-60 minutes before TMZ
- **Common agents**: Ondansetron, metoclopramide

## Safety Parameters and Monitoring

### Prerequisites for Each Cycle
- **ANC**: ≥1.5 × 10⁹/L
- **Platelets**: ≥100 × 10⁹/L
- **Performance status**: Adequate for continuation

### Dose Modifications
- **Grade 3-4 thrombocytopenia**: Hold until recovery, reduce by 50 mg/m²
- **Grade 3-4 neutropenia**: Hold until recovery, reduce by 50 mg/m²
- **Non-hematologic toxicity**: Case-by-case assessment

### Monitoring Schedule
- **Concomitant phase**: Weekly CBC with differential
- **Maintenance phase**: CBC day 22 and day 29 of each cycle
- **Additional**: LFTs, renal function as clinically indicated

## Alternative Dosing Regimens

### Dose-Dense Schedule (Investigational)
- **Week 1**: 75-100 mg/m² daily × 7 days
- **Weeks 2-3**: Rest period
- **Cycle length**: 21 days
- **Status**: Under clinical investigation

### Low-Dose Continuous
- **Dose**: 50 mg/m² daily continuously
- **Duration**: Until progression
- **Indication**: Elderly or poor PS patients

## Hospital-Specific Protocols

### NHS (UK) Protocol Highlights
- **Standard dose**: 150 mg/m² (from UHS guidelines)
- **Concurrent RT**: Standard approach
- **Maintenance**: Following established protocols
- **Safety monitoring**: Enhanced hematological surveillance

## Special Populations

### Elderly Patients (≥70 years)
- **Consideration**: Reduced intensity regimens
- **Option**: Hypofractionated RT + concurrent TMZ
- **Monitoring**: More frequent assessments

### Poor Performance Status
- **Alternative**: TMZ alone (without RT)
- **Dose**: Standard or reduced based on tolerance
- **Goal**: Palliative benefit

## Key Drug Interactions
- **Valproic acid**: May increase TMZ levels
- **Live vaccines**: Avoid during treatment
- **CYP450**: Minimal interactions due to non-enzymatic metabolism

*Compiled from NCCN Guidelines, FDA labeling, and current clinical literature (2024)*